Westie Jaw

Westie Jaw, formally known as craniomandibular osteopathy (CMO), is a non-neoplastic proliferative bone disease that affects the mandible, tympanic bullae, and occasionally other flat bones of the skull in young, growing dogs. The condition is characterized by irregular and excessive new bone formation that replaces normal bone tissue, leading to thickened, often painful, jaw structures. Although the name suggests that only West Highland White Terriers are affected, the condition occurs across several breeds and even in mixed-breed dogs on rare occasions.

The disease typically presents between four and eight months of age, during a period of rapid skeletal development. During this time, normal bone remodeling is disrupted and replaced by a cycle of bone resorption followed by the deposition of coarse, woven bone. This abnormal bone is structurally inferior to mature lamellar bone and is responsible for the swollen, lumpy appearance of the jaw that owners often notice first. The proliferative bone growth can extend along the entire length of the mandible and may involve the temporomandibular joint.

Craniomandibular osteopathy is considered a self-limiting disease in most cases, meaning that the abnormal bone growth tends to slow and eventually stop as the dog reaches skeletal maturity, typically around one year of age. However, the degree of functional impairment varies widely. Some dogs experience only mild jaw thickening with minimal discomfort, while others develop severe bone proliferation that restricts jaw movement and makes eating extremely difficult. The variability in outcome makes early diagnosis and supportive care critical.

Research into the condition has identified an autosomal recessive mode of inheritance in West Highland White Terriers, with a specific genetic mutation linked to the disease. This genetic basis explains the strong breed predisposition and has allowed breeders to use genetic testing to reduce the incidence in affected lines. Despite the hereditary nature of the condition, environmental factors and the timing of skeletal growth spurts may influence the severity of clinical signs in individual dogs.

The primary cause of craniomandibular osteopathy is genetic. In West Highland White Terriers, the condition follows an autosomal recessive inheritance pattern, meaning that a puppy must inherit two copies of the defective gene, one from each parent, to develop clinical disease. Dogs carrying only one copy of the mutation are typically asymptomatic carriers, which allows the gene to persist silently in breeding populations unless carrier testing is performed. The specific genetic mutation has been mapped and is associated with abnormal regulation of bone metabolism during the growth phase.

Breed predisposition is the most significant risk factor. West Highland White Terriers have the highest prevalence, but Scottish Terriers and Cairn Terriers are also commonly affected. Outside the terrier group, sporadic cases have been documented in Labrador Retrievers, Great Danes, Boxers, Doberman Pinschers, and Boston Terriers. In non-terrier breeds, the inheritance pattern is less clearly defined, and the condition may involve different genetic or environmental triggers. The observation that multiple breeds are affected suggests that more than one genetic pathway can lead to similar patterns of abnormal bone proliferation.

Age is another important factor. Virtually all cases present between three and ten months of age, coinciding with the most active period of skeletal growth. The disease has not been convincingly documented in adult dogs developing the condition de novo, which supports the theory that CMO is fundamentally a disorder of bone development rather than a degenerative or acquired disease. The hormonal and metabolic changes associated with rapid growth appear to create the conditions under which the abnormal bone remodeling process is triggered in genetically susceptible individuals.

While infectious causes were historically considered, no virus, bacterium, or other pathogen has been consistently isolated from affected bone tissue. Similarly, nutritional factors such as calcium or phosphorus imbalances have been investigated but have not been shown to cause the condition. The current consensus is that CMO is a genetically determined disorder of bone metabolism, and external factors play at most a modifying role in determining the severity of clinical expression.

The hallmark symptom of craniomandibular osteopathy is bilateral swelling of the mandible, which gives the jaw a thickened, lumpy appearance that can often be felt through the skin. Owners may first notice the swelling when petting or handling the puppy's head, or they may observe that the dog's face appears unusually broad or asymmetrical. The bony enlargements are typically firm and non-movable, distinguishing them from soft tissue swellings caused by infection or trauma. In some cases, the tympanic bullae at the base of the skull are also enlarged, giving the head a rounded or bulging appearance behind the ears.

Pain is a prominent clinical feature and often the first sign that prompts veterinary attention. Affected puppies may cry out when yawning, chewing, or having their mouths opened for examination. They may become reluctant to eat or may approach the food bowl with interest but pull away after attempting to chew. Drooling is common, and some dogs develop a preference for soft or liquid foods because hard kibble causes too much discomfort. The pain tends to be episodic, with periods of intense discomfort alternating with relatively comfortable intervals, reflecting the cyclical nature of the bone remodeling process.

Systemic signs frequently accompany the jaw pain. Intermittent fever, sometimes reaching 104 to 106 degrees Fahrenheit, is a characteristic feature and may occur in recurring episodes that coincide with active phases of bone proliferation. During febrile episodes, puppies may become lethargic, refuse all food, and show signs of general malaise. Weight loss or failure to gain weight at an appropriate rate is a common secondary consequence, particularly in severely affected dogs that cannot eat enough to meet their nutritional needs during the critical growth period.

In advanced cases, the abnormal bone growth may extend to the temporomandibular joint, causing mechanical restriction of jaw movement. Dogs with TMJ involvement may be unable to open their mouths fully, a condition known as trismus. Severe trismus can make eating nearly impossible without intervention and represents the most serious functional consequence of the disease. Some dogs also develop muscle atrophy in the temporal and masseter muscles due to disuse, further contributing to the altered facial appearance.

Diagnosis of craniomandibular osteopathy is based on a combination of signalment, clinical signs, and radiographic findings. The typical presentation of a young terrier breed puppy with bilateral mandibular swelling, jaw pain, and intermittent fever is highly suggestive, but imaging is essential to confirm the diagnosis and assess the extent of bone involvement. A thorough physical examination, including careful palpation of the mandibles and skull, provides important initial information about the location and extent of the bony proliferation.

Radiography is the primary diagnostic imaging modality. Lateral and ventrodorsal skull radiographs reveal characteristic bilateral, irregular periosteal new bone formation along the mandibles. The new bone has a rough, mottled appearance that contrasts with the smooth cortical surface of normal mandibular bone. In many cases, the tympanic bullae also show increased opacity and irregular bony thickening. The radiographic pattern is sufficiently distinctive that it can usually be differentiated from other causes of mandibular swelling, such as osteomyelitis, neoplasia, or metabolic bone disease, without the need for biopsy in straightforward cases.

Computed tomography (CT) provides superior detail compared to conventional radiography and is particularly valuable for assessing involvement of the temporomandibular joints and tympanic bullae. CT scanning can reveal the full three-dimensional extent of the bony proliferation and identify subtle TMJ changes that may not be apparent on standard radiographs. This information is important for prognostic purposes, as TMJ involvement carries a higher risk of permanent jaw restriction. CT is increasingly used in referral settings where it is available, though it requires general anesthesia.

Laboratory findings in dogs with CMO are generally nonspecific. Blood work may show mild elevation in alkaline phosphatase, consistent with active bone turnover, and leukocytosis may be present during febrile episodes. These findings support the diagnosis but are not specific to CMO. Biopsy of affected bone is rarely necessary but, when performed, reveals replacement of normal lamellar bone with immature woven bone and fibrous tissue, consistent with a non-neoplastic proliferative process. Genetic testing is available for West Highland White Terriers to identify carriers and affected individuals, and this can be a valuable complement to clinical diagnosis in the breed.

Differential diagnosis should include osteomyelitis secondary to tooth root abscess, neoplasia such as osteosarcoma or multilobular tumor of bone, hypertrophic osteodystrophy, and calvarial hyperostotic syndrome. The bilateral symmetry of CMO, the age of onset, and the breed predisposition are key differentiating features. In older dogs or atypical presentations, biopsy may be warranted to rule out neoplasia definitively.

There is no specific cure for craniomandibular osteopathy, and treatment is focused on managing pain, maintaining adequate nutrition, and supporting the puppy through the active phase of the disease until bone growth stabilizes. The self-limiting nature of the condition means that the therapeutic goal is to keep the dog comfortable and nourished while the disease runs its course. In most cases, the abnormal bone proliferation slows significantly by 11 to 13 months of age, and many dogs experience substantial improvement as they approach skeletal maturity.

Pain management is the cornerstone of treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam or carprofen are commonly prescribed to reduce inflammation and provide analgesia. These medications can be highly effective during painful episodes and may need to be administered intermittently over several months as symptoms wax and wane. In cases where NSAIDs alone are insufficient, corticosteroids such as prednisone may be used during particularly severe flare-ups. Corticosteroids are potent anti-inflammatory agents and can provide dramatic pain relief, but their long-term use carries risks including immunosuppression, gastrointestinal complications, and interference with normal bone development, so they are typically reserved for short courses during acute episodes.

Nutritional support is critical, particularly for severely affected puppies that have difficulty eating. Softening dry food with warm water, offering canned or pureed diets, and providing calorie-dense formulations can help ensure adequate nutritional intake. In some cases, syringe feeding or placement of a feeding tube may be necessary for dogs with severe trismus that cannot open their mouths wide enough to eat voluntarily. Monitoring body weight and growth rate throughout the treatment period helps gauge whether nutritional interventions are sufficient.

Physical therapy and gentle jaw exercises may be beneficial for dogs developing restricted jaw mobility. Under veterinary guidance, gentle range-of-motion exercises can help maintain some degree of jaw opening during the active phase of the disease. However, aggressive manipulation should be avoided as it can cause pain and potentially worsen inflammation. Warm compresses applied to the jaw area may provide additional comfort during painful episodes.

Surgical intervention is rarely indicated but may be considered in extreme cases where bony ankylosis of the temporomandibular joint has occurred and the dog cannot open its mouth sufficiently to eat. Surgical excision of the proliferative bone to restore jaw function carries risks of regrowth and complications and is generally viewed as a last resort. Consultation with a veterinary surgical specialist is advisable when surgery is being considered.

The prognosis for dogs with craniomandibular osteopathy varies considerably depending on the severity of the disease and, most critically, whether the temporomandibular joints are involved. For dogs with mild to moderate mandibular involvement without significant TMJ restriction, the long-term prognosis is generally favorable. The abnormal bone growth typically stabilizes by one year of age, and many dogs go on to live normal, comfortable lives with little or no residual disability. Some degree of permanent mandibular thickening may persist, but this is usually a cosmetic issue rather than a functional one.

Dogs with moderate disease often show gradual improvement over several months as active bone proliferation ceases and the immature woven bone is slowly remodeled into more organized lamellar bone. This remodeling process can continue for months after the acute phase has ended and may result in partial regression of the bony enlargements. During the recovery period, pain typically decreases and appetite returns to normal, allowing the dog to regain any lost weight and resume normal activity levels.

The prognosis is more guarded for dogs with severe TMJ involvement. Bony ankylosis or near-ankylosis of the temporomandibular joints can result in permanent restriction of jaw opening, which may compromise the dog's ability to eat, groom, and pant effectively for thermoregulation. In the most severe cases, where the jaw cannot be opened more than a few millimeters, the quality of life may be so compromised that humane euthanasia is considered. Fortunately, complete bilateral ankylosis is relatively uncommon, and most dogs retain at least some degree of functional jaw movement.

Long-term follow-up studies in West Highland White Terriers suggest that the majority of affected dogs achieve a good quality of life after the active phase of the disease resolves. Regular veterinary monitoring during the first two years of life is recommended to track the progress of bone remodeling and to address any residual functional limitations. Dogs that have recovered from CMO do not appear to be at increased risk for other bone diseases later in life, and their overall life expectancy is generally not affected by the condition unless severe complications occurred during the active phase.

West Highland White Terriers have the strongest association with craniomandibular osteopathy, and the condition is sometimes referred to as Westie Jaw specifically because of this breed's high prevalence. Studies in the breed have identified the autosomal recessive inheritance pattern and the specific genetic mutation responsible, making Westies the most thoroughly studied breed with respect to this condition. The availability of genetic testing in this breed has allowed responsible breeders to identify carriers and make informed breeding decisions to reduce the incidence of CMO in future generations.

Scottish Terriers represent the second most commonly affected breed. The clinical presentation in Scottish Terriers is generally similar to that seen in Westies, with bilateral mandibular swelling and intermittent fever during the growth period. The close phylogenetic relationship between Scottish Terriers and West Highland White Terriers suggests that the same or a closely related genetic mutation may be responsible for the condition in both breeds. Cairn Terriers are also affected with notable frequency, further supporting the idea of a shared genetic basis among the closely related terrier breeds that originated in Scotland.

Outside the terrier group, craniomandibular osteopathy has been documented in several large and giant breeds, including Labrador Retrievers, Great Danes, Boxers, and Doberman Pinschers. In these breeds, the condition appears to occur sporadically rather than following a clear familial pattern, and the genetic basis, if any, has not been characterized as thoroughly as in terriers. Some researchers have suggested that CMO in large breeds may represent a related but distinct disorder with different genetic underpinnings, as the clinical features can differ somewhat from the classic terrier presentation.

Boston Terriers, English Bulldogs, and occasionally other brachycephalic breeds have also been reported to develop CMO. The condition has been documented in mixed-breed dogs as well, though this is uncommon. The wide range of affected breeds underscores the fact that craniomandibular osteopathy is not exclusively a Westie disease, and veterinarians should consider the diagnosis in any young dog presenting with bilateral mandibular swelling and pain, regardless of breed. Awareness of the broader breed susceptibility helps ensure timely diagnosis and appropriate management in less commonly affected populations.

The identification of the genetic mutation responsible for craniomandibular osteopathy in West Highland White Terriers has been a significant advance in managing the condition at the population level. The mutation follows an autosomal recessive inheritance pattern, meaning that dogs can be classified as clear (no copies of the mutation), carriers (one copy), or affected (two copies). Genetic testing using a simple cheek swab or blood sample can determine a dog's status, allowing breeders to make informed decisions about which dogs to pair in breeding programs.

Responsible breeding practices recommend testing all breeding stock for the CMO mutation before mating. Ideally, at least one parent in every pairing should be genetically clear to ensure that no puppies in the litter will be affected by the disease. Carrier-to-clear matings will produce a statistical proportion of carriers in the litter but no affected puppies, allowing breeders to gradually reduce the carrier frequency in the population over successive generations without overly restricting the gene pool. Carrier-to-carrier matings should be avoided, as they carry a 25 percent risk of producing affected offspring.

The availability of genetic testing has placed an ethical responsibility on breeders to use these tools proactively. Breed clubs for West Highland White Terriers, Scottish Terriers, and Cairn Terriers have increasingly incorporated CMO testing recommendations into their breeding guidelines and health screening protocols. Some kennel clubs and breed organizations now require or strongly recommend CMO testing as part of their breeding certification programs. Prospective puppy buyers are also encouraged to ask breeders about the CMO status of both parents before purchasing a puppy from a susceptible breed.

For breeds outside the terrier group where the specific genetic mutation has not been identified, breeding recommendations rely on pedigree analysis and clinical history. Dogs that have produced affected offspring should be considered carriers and bred only to partners with no family history of the condition. As genetic research continues to advance, it is hoped that additional breed-specific mutations will be identified, expanding the availability of genetic testing to a broader range of affected breeds. Until then, careful pedigree evaluation and open sharing of health information among breeders remain the primary tools for reducing the incidence of CMO in these populations.

Caring for a puppy diagnosed with craniomandibular osteopathy requires patience, attentiveness, and a commitment to maintaining the dog's comfort and nutrition through what can be a challenging period. The episodic nature of the disease, with unpredictable flare-ups of pain and fever, can be stressful for both the dog and the owner. Understanding the natural history of the condition and knowing that it is self-limiting in most cases can provide reassurance during difficult episodes and help owners maintain a positive outlook throughout the treatment period.

Daily management during active phases centers on pain monitoring and dietary adaptation. Owners should learn to recognize the signs of a pain flare-up, which may include reluctance to eat, excessive drooling, whimpering when yawning or playing with toys, and general lethargy. Keeping a log of symptoms, appetite, and medication administration can be helpful for tracking the disease course and communicating effectively with the veterinarian. Temperature monitoring at home may also be recommended, as febrile episodes often accompany periods of active bone proliferation.

Mealtime modifications are often necessary and can make a significant difference in the dog's nutritional intake and comfort. Elevated food bowls can reduce the need for the dog to lower its head and strain the jaw. Warming food slightly can make it more aromatic and appealing to dogs with reduced appetite. For dogs with significant jaw restriction, blending food into a gruel consistency or using high-calorie nutritional supplements can help maintain caloric intake. Multiple small meals throughout the day may be better tolerated than two or three larger meals, as smaller portions require less sustained chewing effort.

Socialization and mental stimulation should continue as much as the dog's comfort allows. While hard chew toys should be avoided during active phases to prevent jaw pain, soft toys, puzzle feeders with easy-to-access treats, and gentle play can help maintain the puppy's mental well-being and social development. Restricting all activity is unnecessary and can lead to behavioral issues. As the dog matures and symptoms resolve, normal activities including appropriate chew toys can typically be gradually reintroduced.

Emotional support for the owner is also an important consideration. Caring for a chronically painful puppy can be emotionally draining, and connecting with breed-specific support groups or online communities of owners who have managed CMO can provide valuable practical advice and emotional encouragement. Many owners of dogs that have recovered from CMO report that the difficult early months were followed by years of happy, healthy companionship.

Current research into craniomandibular osteopathy continues to explore the molecular mechanisms underlying the abnormal bone remodeling that characterizes the disease. Advances in canine genomics have enabled researchers to move beyond identifying the causative mutation to understanding how the mutation disrupts normal osteoblast and osteoclast function at the cellular level. This deeper understanding of the disease pathophysiology may eventually lead to targeted therapeutic interventions that can modulate the bone remodeling process rather than simply managing symptoms.

Comparative medicine studies have drawn parallels between CMO in dogs and infantile cortical hyperostosis (Caffey disease) in humans. Both conditions involve excessive periosteal new bone formation during the growth period, are self-limiting, and have a genetic basis. The similarities between these conditions have made CMO in dogs a valuable natural animal model for studying Caffey disease, and findings from canine research may contribute to understanding and treating the human condition. This cross-species research collaboration benefits both veterinary and human medicine.

Pharmacological research is investigating whether bisphosphonates or other bone-modifying agents could be used to control the excessive bone proliferation in severely affected dogs. Bisphosphonates are widely used in human medicine to treat conditions involving excessive bone resorption and have shown promise in some veterinary applications. However, their use in growing animals raises concerns about potential effects on normal skeletal development, and controlled clinical trials are needed to establish their safety and efficacy in young dogs with CMO.

Genetic research continues to focus on identifying the mutations responsible for CMO in breeds other than West Highland White Terriers. Genome-wide association studies in Scottish Terriers, Cairn Terriers, and affected large breeds are underway at several veterinary research institutions. Identifying additional mutations would expand the availability of genetic testing and provide further insights into the genetic heterogeneity of the condition. Additionally, epigenetic studies are exploring whether environmental factors such as nutrition or stress during the growth period can influence the expression and severity of the disease in genetically susceptible individuals, potentially opening new avenues for preventive management strategies.